- Home
- BCV vs ACHV Comparison
BCV vs ACHV Comparison
Compare BCV & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- ACHV
- Stock Information
- Founded
- BCV 1971
- ACHV N/A
- Country
- BCV United States
- ACHV United States
- Employees
- BCV N/A
- ACHV N/A
- Industry
- BCV Finance/Investors Services
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCV Finance
- ACHV Health Care
- Exchange
- BCV Nasdaq
- ACHV Nasdaq
- Market Cap
- BCV 130.9M
- ACHV 153.8M
- IPO Year
- BCV N/A
- ACHV N/A
- Fundamental
- Price
- BCV N/A
- ACHV $3.45
- Analyst Decision
- BCV
- ACHV Strong Buy
- Analyst Count
- BCV 0
- ACHV 1
- Target Price
- BCV N/A
- ACHV $12.00
- AVG Volume (30 Days)
- BCV 26.3K
- ACHV 796.5K
- Earning Date
- BCV 01-01-0001
- ACHV 11-06-2025
- Dividend Yield
- BCV 8.13%
- ACHV N/A
- EPS Growth
- BCV N/A
- ACHV N/A
- EPS
- BCV N/A
- ACHV N/A
- Revenue
- BCV N/A
- ACHV N/A
- Revenue This Year
- BCV N/A
- ACHV N/A
- Revenue Next Year
- BCV N/A
- ACHV N/A
- P/E Ratio
- BCV N/A
- ACHV N/A
- Revenue Growth
- BCV N/A
- ACHV N/A
- 52 Week Low
- BCV $14.09
- ACHV $1.84
- 52 Week High
- BCV $18.11
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- BCV 77.78
- ACHV 65.88
- Support Level
- BCV $21.54
- ACHV $3.07
- Resistance Level
- BCV $22.05
- ACHV $3.26
- Average True Range (ATR)
- BCV 0.34
- ACHV 0.14
- MACD
- BCV 0.04
- ACHV 0.02
- Stochastic Oscillator
- BCV 100.00
- ACHV 99.80
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.